Phenobarbital
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Phenobarbital: From Antiseizure Therapy to Trigeminal Nerve Neoplasm
One-Sentence Summary
Phenobarbital is a barbiturate widely known as an antiseizure and sedative medicine. The TxGNN model ranks trigeminal nerve neoplasm as its top predicted new indication. This prediction has 0 clinical trials and 1 publication behind it, and that publication does not address tumours, so the evidence is model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the SAHPRA licence data (phenobarbital is an established antiseizure drug) |
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Phenobarbital is generally understood to enhance GABA-A receptor-mediated inhibition, which underlies its antiseizure and sedative effects. It has no known antineoplastic activity.
The link to trigeminal nerve neoplasm is not plausible on mechanistic grounds. The very high score (99.96%) most likely reflects proximity in the knowledge graph through trigeminal- or seizure-related nodes, not a therapeutic relationship. The only paper retrieved concerns Sturge-Weber syndrome, where phenobarbital is used to control seizures, not to treat a tumour.
Other predictions for this drug have a more coherent biological rationale, although the evidence is still indirect:
- Reflex or trigger-specific seizure types, namely thinking, startle, audiogenic, eating, micturition-induced, orgasm-induced and reading seizures. GABA-A potentiation is a plausible class-level rationale.
- Trigeminal neuralgia. Anticonvulsants are standard therapy, but carbamazepine leads. Phenobarbital appears mainly as an enzyme inducer that lowers carbamazepine levels, not as an effective treatment.
Clinical Trial Evidence
Currently no related clinical trials registered for trigeminal nerve neoplasm (ClinicalTrials.gov, ICTRP; no SANCTR or PACTR entries were retrieved).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9157801 | 1997 | Case series | Anales espanoles de pediatria | Review of 14 Sturge-Weber syndrome cases over 25 years covering clinical features, evolution and treatment response. It does not evaluate phenobarbital for any tumour. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| B1233 (OM) | Propain forte | Tablet (oral) | Not stated in the retrieved record |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction rests on a model score alone (L5). There is no mechanistic plausibility, no clinical trials, and no supporting literature. The single publication is about seizure control in Sturge-Weber syndrome. The local safety data needed for screening are also missing.
To proceed, the following is needed:
- The SAHPRA package insert (warnings and contraindications). This is a blocking gap.
- Mechanism of action data from DrugBank.
- The approved indication text for the local registration (Propain forte).
- Confirmation of whether the product is single-ingredient phenobarbital or a combination product.
- A review of the lower-ranked seizure-related predictions as research questions. Reading seizures, micturition-induced seizures, thinking seizures, startle epilepsy and trigeminal neuralgia reached L4 evidence, but the retrieved evidence is indirect. No trials test phenobarbital in these specific conditions.
These results are for research reference only and do not constitute medical advice. Any repurposing candidate requires clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.